Catheter Precision Announces Tender Win and First Purchase Order in Croatia
Catheter Precision (NYSE:VTAK) has secured its first purchase order from Croatia's Dubrava University Hospital following a successful competitive tender bid. The hospital, which treats over 25,000 inpatients and provides healthcare services to more than 400,000 outpatients annually, completed an evaluation of VTAK's VIVO cardiac mapping technology.
Dr. Ivan Zeljkovic, Head of Electrophysiology Lab at Dubrava, praised VIVO's workflow simplicity, mapping accuracy, and potential to enhance procedural efficacy in targeting ventricular arrhythmia locations. This development marks a significant expansion into the European healthcare market for Catheter Precision's cardiac electrophysiology technology.
Catheter Precision (NYSE:VTAK) ha ottenuto il suo primo ordine di acquisto dall'Ospedale Universitario Dubrava in Croazia dopo aver vinto una gara competitiva. L'ospedale, che cura oltre 25.000 pazienti ricoverati e offre servizi sanitari a pi霉 di 400.000 pazienti ambulatoriali all'anno, ha completato la valutazione della tecnologia di mappatura cardiaca VIVO di VTAK.
Il dott. Ivan Zeljkovic, responsabile del laboratorio di elettrofisiologia di Dubrava, ha elogiato la semplicit脿 del flusso di lavoro di VIVO, la precisione della mappatura e il potenziale di migliorare l'efficacia delle procedure nel localizzare le aritmie ventricolari. Questo traguardo rappresenta un'importante espansione nel mercato sanitario europeo per la tecnologia di elettrofisiologia cardiaca di Catheter Precision.
Catheter Precision (NYSE:VTAK) ha asegurado su primer pedido de compra del Hospital Universitario Dubrava de Croacia tras ganar una licitaci贸n competitiva. El hospital, que atiende a m谩s de 25.000 pacientes ingresados y presta servicios a m谩s de 400.000 pacientes ambulatorios al a帽o, complet贸 la evaluaci贸n de la tecnolog铆a de mapeo card铆aco VIVO de VTAK.
El Dr. Ivan Zeljkovic, jefe del laboratorio de electrofisiolog铆a de Dubrava, destac贸 la sencillez del flujo de trabajo de VIVO, la precisi贸n del mapeo y su potencial para mejorar la eficacia de los procedimientos al localizar arritmias ventriculares. Este avance supone una relevante expansi贸n en el mercado sanitario europeo para la tecnolog铆a de electrofisiolog铆a cardiaca de Catheter Precision.
Catheter Precision (NYSE:VTAK)電� 瓴届焷 鞛呾鞍鞐愳劀 靹标车鞚� 瓯半憯 霋� 韥鞎勴嫲鞎� 霊愲笇霛茧皵 雽�頃欕硲鞗愳溂搿滊秬韯� 觳� 甑Г 欤茧鞚� 頇曤炒頄堨姷雼堧嫟. 鞐瓣皠 25,000氇� 鞚挫儊鞚� 鞛呾洂頇橃瀽鞕� 400,000氇� 鞚挫儊鞚� 鞕鸽灅頇橃瀽鞐愱矊 鞚橂 靹滊箘鞀るゼ 鞝滉车頃橂姅 鞚� 氤戩洂鞚� VTAK鞚� VIVO 鞁灔 歆�霃勴檾 旮办垹鞚� 韽夑皜頄堨姷雼堧嫟.
霊愲笇霛茧皵 鞝勱赴靸濍Μ頃欖嫟鞛レ澑 鞚措皹 鞝れ綌牍勳箻 氚曥偓電� VIVO鞚� 鞛戩梾 頋愲 臧勱舶靹�, 歆�霃勴檾 鞝曧檿靹�, 攴鸽Μ瓿� 鞁嫟靹� 攵�鞝曤Д 鞙勳箻 響滌爜頇� 鞁� 鞁滌垹 須湪靹膘潉 雴掛澕 鞛犾灛霠レ潉 雴掛澊 韽夑皜頄堨姷雼堧嫟. 鞚� 靹标臣電� Catheter Precision鞚� 鞁灔 鞝勱赴靸濍Μ頃� 旮办垹鞚� 鞙犽熃 鞚橂 鞁滌灔鞙茧 韥矊 頇曥灔霅� 瓴冹潉 鞚橂頃╇媹雼�.
Catheter Precision (NYSE:VTAK) a obtenu sa premi猫re commande aupr猫s de l'H么pital universitaire Dubrava en Croatie apr猫s avoir remport茅 un appel d'offres comp茅titif. L'h么pital, qui prend en charge plus de 25 000 patients hospitalis茅s et fournit des soins 脿 plus de 400 000 patients externes par an, a men茅 l'茅valuation de la technologie de cartographie cardiaque VIVO de VTAK.
Le Dr Ivan Zeljkovic, responsable du laboratoire d'茅lectrophysiologie de Dubrava, a salu茅 la simplicit茅 du flux de travail de VIVO, la pr茅cision de sa cartographie et son potentiel 脿 am茅liorer l'efficacit茅 des proc茅dures pour cibler les localisations d'arythmies ventriculaires. Cette avanc茅e marque une expansion significative sur le march茅 europ茅en des technologies d'茅lectrophysiologie cardiaque de Catheter Precision.
Catheter Precision (NYSE:VTAK) hat nach einem erfolgreichen wettbewerblichen Ausschreibungsverfahren seinen ersten Auftrag vom Universit盲tsklinikum Dubrava in Kroatien erhalten. Das Krankenhaus, das j盲hrlich mehr als 25.000 station盲re Patienten behandelt und 眉ber 400.000 ambulante Behandlungen durchf眉hrt, hat die VIVO-Herzkartierungstechnologie von VTAK bewertet.
Dr. Ivan Zeljkovic, Leiter des Elektrophysiologie-Labors in Dubrava, lobte die einfache Arbeitsweise von VIVO, die Genauigkeit der Kartierung und das Potenzial, die Verfahrenswirksamkeit bei der Lokalisation ventrikul盲rer Arrhythmien zu steigern. Diese Entwicklung markiert eine bedeutende Ausweitung von Catheter Precisions kardiologischer Elektrophysiologie-Technologie auf den europ盲ischen Gesundheitsmarkt.
- Successful tender win at major Croatian hospital indicates product competitiveness
- Positive clinical feedback from Head of Electrophysiology Lab validates technology effectiveness
- Entry into Croatian market expands European presence
- Large potential patient base with hospital serving 400,000+ outpatients annually
- None.
Insights
Catheter Precision secures Croatian hospital contract for VIVO technology, marking strategic European market entry with revenue-generating potential.
Catheter Precision's announcement represents a notable market expansion milestone for their VIVO cardiac mapping technology. Winning this competitive tender at Dubrava University Hospital - one of Croatia's leading medical institutions treating over 400,000 outpatients annually - establishes an important European foothold.
The endorsement from Dr. Zeljkovic, Head of Electrophysiology, highlighting VIVO's accuracy and potential to increase procedural efficacy in ventricular arrhythmia treatment, provides crucial clinical validation. This suggests the technology delivers meaningful clinical advantages over competing solutions in the cardiac electrophysiology space.
From a commercialization perspective, this represents Catheter Precision's first revenue-generating customer in Croatia, following their previously announced evaluation period. The tender process victory demonstrates the company's ability to successfully navigate European procurement systems, which typically involve rigorous evaluation against established competitors.
While a single hospital contract isn't transformative financially, it functions as a strategic reference site in the EMEA region that could accelerate adoption across similar institutions. Dubrava's status as a teaching hospital with research departments further enhances the potential for VIVO to gain visibility among clinicians training there, potentially driving future utilization.
This achievement aligns with Catheter Precision's international expansion strategy, as evidenced by their dedicated EMEA & APAC Sales Manager's involvement, suggesting a structured approach to building their European presence rather than an opportunistic sale.
FORT MILL, S.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received the first purchase order from a hospital in Croatia after winning a competitive tender bid.
As previously announced, Dubrava Hospital completed an evaluation before placing VIVO into the bid process for purchase approval. The biding process allows the hospital to evaluate competitive products and decide whether to allow the product into the hospital and subsequent purchase. At the time of the evaluation, Dr. Ivan Zeljkovic, Head of Electrophysiology Lab at聽Dubrava聽University Hospital stated, "The VIVO workflow is simple and flexible, and I was impressed with the accuracy of the VIVO maps which certainly exceeded my expectations! Having the VIVO maps pre-procedurally allowed us to accurately target the anatomic location of the ventricular arrhythmia and has the potential to increase procedural efficacy."
, located in Zagreb, Croatia, is one of the leading hospitals in the country. Annually, more than 25,000 patients are treated in inpatient departments, while more than 1,500,000 health services are provided to more than 400,000 patients in the outpatient department. In addition, it is a teaching hospital and boasts several research departments.
鈥淭his milestone represents more than just geographic expansion鈥攊t reflects the trust and enthusiasm of leading clinicians and partners across Europe who are embracing our technologies to elevate patient care,鈥澛爏aid Fatih Ayoglu, Sales Manager for EMEA & APAC at Catheter Precision Inc. 鈥淲e鈥檙e proud to collaborate with such forward-thinking institutions and physicians and look forward to continued growth across the region.鈥�
About VIVO鈩�
Catheter Precision鈥檚 (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as 鈥渂elieve,鈥� 鈥渁nticipate,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渃an,鈥� 鈥渃ould,鈥� 鈥渃ontinue,鈥� 鈥渄epends,鈥� 鈥渆xpect,鈥� 鈥渆xpand,鈥� 鈥渇orecast,鈥� 鈥渋ntend,鈥� 鈥減redict,鈥� 鈥減lan,鈥� 鈥渞ely,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渟eek,鈥� or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. 聽These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company鈥檚 expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption 鈥淩isk Factors鈥� in the Company鈥檚 Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
# # #
FAQ
What did Catheter Precision (VTAK) announce about its expansion in Croatia?
How many patients does Dubrava University Hospital treat annually?
What are the key benefits of VTAK's VIVO technology according to Dr. Zeljkovic?
Who is leading Catheter Precision's sales efforts in the EMEA & APAC regions?
What type of medical technology does Catheter Precision (VTAK) develop?
